ArticlePathology oncology research : POR2021
Discordance in ER, PR, HER2, and Ki-67 Expression Between Primary and Recurrent/Metastatic Lesions in Patients with Primary Early Stage Breast Cancer and the Clinical Significance: Retrospective Analysis of 75 Cases.
Article in Pathology oncology research : POR, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- HER2-low metastatic breast cancers: clinic-pathological characteristics, metastatic sites, and survival impact on biomarker discordance.Virchows Archiv : an international journal of pathology · 2026Article
- Rationale and Trial Design of DAWNA-FES Trial: Single-Arm Phase II Study of Endocrine Therapy With Dalpiciclib After Progression on CDK4/6 Inhibition Based on [Cancer innovation · 2026Article
- The Current Landscape of Metastatic Breast Cancer: A Pathology Guide on Emerging Biomarkers.Cancers · 2026Review
- Variations in histopathological and molecular subtypes between primary breast carcinoma and associated liver metastatic lesions.Frontiers in oncology · 2026Article
- Post-Surgical Reassessment of Breast Cancer IHC: Concordance, Δ-Metrics, and Treatment-Relevant Reclassification.Diagnostics (Basel, Switzerland) · 2025Article
- Prognostic value of the systemic immune-inflammation index in recurrent/metastatic triple-negative breast cancer: a retrospective cohort study.Gland surgery · 2025Article
- Article
- Beyond the Tumor: Invasive Fungal Infection Unveiled in HER2-Positive Breast Cancer Patient Mimicking Disease Relapse.Journal of cancer & allied specialties · 2025Article
- Article
- Partial response to trastuzumab deruxtecan (DS8201) following progression in HER2-amplified breast cancer with pulmonary metastases managed with disitamab vedotin (RC48): a comprehensive case report and literature review.Frontiers in oncology · 2024Article
- The Association between ER, PR, HER2, and ER-/PR+ Expression and Lung Cancer Subsequent in Breast Cancer Patients: A Retrospective Cohort Study Based on SEER Database.The breast journal · 2023Article
- Expression changes of ER, PR, HER2, and Ki-67 in primary and metastatic breast cancer and its clinical significance.Frontiers in oncology · 2023Article
- Circulating tumor cell assay to non-invasively evaluate PD-L1 and other therapeutic targets in multiple cancers.PloS one · 2022Article
- Breast Cancer Heterogeneity.Diagnostics (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.